European Child & Adolescent Psychiatry

, Volume 14, Issue 6, pp 305–309 | Cite as

12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH

  • Peter Hoare
  • H. Remschmidt
  • R. Medori
  • C. Ettrich
  • A. Rothenberger
  • P. Santosh
  • M. Schmit
  • Q. Spender
  • R. Tamhne
  • M. Thompson
  • C. Tinline
  • G. E. Trott
ORIGINAL CONTRIBUTION

Abstract

Purpose

The aim of this study was to evaluate long-term clinical treatment with OROS® methylphenidate (MPH) (Concerta®) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH.

Methods

Subjects aged 6–16 years (n=105) who were stable on IR MPH (10–60 mg/day) were switched to 18, 36 or 54mg OROS® MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS® MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators.

Results

Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10–16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS® MPH was well tolerated.

Conclusions

Children and adolescents can effectively and safely be switched from IR MPH to OROS® MPH with improved symptom control and compliance.

Key words

ADHD CONCERTA® methylphenidate OROS® long-term treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Academy of Child and Adolescent Psychiatry (1997) Practice parameter for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactive disorder. J Am Acad Child Adolesc Psychiatry 36 (Suppl): 85S–121S www.aacap.org/clinical/Adhdsum.htm.Accessed 10 May 2004PubMedGoogle Scholar
  2. 2.
    Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S; American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(2 Suppl):26S–49SPubMedGoogle Scholar
  3. 3.
    Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11–28CrossRefPubMedGoogle Scholar
  4. 4.
    Loney J, Milich R (1982) Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh DK (eds) Advances in Development and Behavioral Pediatrics. JAI Press. Greenwich, CT, pp 113–147Google Scholar
  5. 5.
    Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1993) Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565–576PubMedGoogle Scholar
  6. 6.
    National Institute for Clinical Excellence (2002) Technology Appraisal Guidance-No 13. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood. October. www.nice.org.uk/article.asp?a = 11667. Accessed 10 May 2004Google Scholar
  7. 7.
    Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN,Morse GD (2001) Once- a-day Concerta methylphenidate versus threetimes-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105CrossRefPubMedGoogle Scholar
  8. 8.
    Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmit M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R (in press) Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH: results of a 3-week open-label study. Eur Child Adolesc PsychiatryGoogle Scholar
  9. 9.
    Stein MA, Greenhill LL (2002) Oncedaily Concerta (MPH) for adolescents and adults with ADHD. Int J Neuropsychopharmacol 5(Suppl 1):S162Google Scholar
  10. 10.
    Wilens TE (2002) Treatment of ADHD with once-daily OROS methylphenidate: results from a long-term openlabel study. Presented at 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18–22Google Scholar
  11. 11.
    Wilens TE (personal communication) A multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorderGoogle Scholar
  12. 12.
    Wilens T, Pelham W, Stein MA,Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424–433PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2005

Authors and Affiliations

  • Peter Hoare
    • 1
  • H. Remschmidt
    • 2
  • R. Medori
    • 3
  • C. Ettrich
    • 4
  • A. Rothenberger
    • 5
  • P. Santosh
    • 6
  • M. Schmit
    • 7
  • Q. Spender
    • 8
  • R. Tamhne
    • 9
  • M. Thompson
    • 10
  • C. Tinline
    • 11
  • G. E. Trott
    • 12
  1. 1.Child and Family Mental Health ServiceRoyal Hospital for Sick ChildrenEdinburgh EH9 1LLUK
  2. 2.Klinik für Psychiatrie und Psychotherapie des Kindes- und JugendaltersMarburgGermany
  3. 3.Janssen-Cilag Europe, Middle-East, AfricaNeussGermany
  4. 4.Kinder- und Jugendpsychiatrie der Universität Leipzig, Dritte EtageLeipzigGermany
  5. 5.Kinder und Jugendpsychiatrie der Georg-August UniversitätGöttingenGermany
  6. 6.Maudsley Hospital, Institute of PsychiatryLondon SE5 8AFUK
  7. 7.Kinder- und Jugendpsychiatrie Klinik Zentralinstitut für seelische GesundheitMannheimGermany
  8. 8.Orchard House Sussex Weald and Downs NHS TrustChichester PO19 4PQUK
  9. 9.Leicestershire and Rutland Healthcare TrustThurmaston, Leicester LE4 8PQUK
  10. 10.Ashurst Hospital, Department of PsychiatryLyndhurst, Southampton SO40 7ARUK
  11. 11.The Pear Tree Centre Child and Family Therapy Service, Smallwood HouseRedditch, Worcestershire B97 4BDUK
  12. 12.PrivatpraxisAschaffenburgGermany

Personalised recommendations